Arjun Agarwal Sells 1,587 Shares of Oruka Therapeutics (NASDAQ:ORKA) Stock

Oruka Therapeutics, Inc. (NASDAQ:ORKA) SVP Arjun Agarwal sold 1,587 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $80.95, for a total transaction of $128,467.65. Following the completion of the transaction, the senior vice president owned 15,312 shares of the company’s stock, valued at $1,239,506.40. This represents a 9.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arjun Agarwal also recently made the following trade(s):

• On Monday, June 15th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The shares were sold at an average price of $69.69, for a total transaction of $27,527.55.
• On Friday, June 12th, Arjun Agarwal sold 9,459 shares of Oruka Therapeutics stock. The stock was sold at an average price of $69.72, for a total value of $659,481.48.
• On Monday, May 18th, Arjun Agarwal sold 10,290 shares of Oruka Therapeutics stock. The stock was sold at an average price of $59.07, for a total value of $607,830.30.

Oruka Therapeutics Stock Performance

Shares of NASDAQ ORKA opened at $83.40 on Wednesday. The stock has a market cap of $5.03 billion, a PE ratio of -42.99 and a beta of -0.26. Oruka Therapeutics, Inc. has a fifty-two week low of $10.79 and a fifty-two week high of $91.00. The stock has a fifty day moving average of $65.64 and a 200-day moving average of $46.27.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.04. On average, sell-side analysts predict that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Analyst Ratings Changes

ORKA has been the topic of a number of analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $120.00 target price on shares of Oruka Therapeutics in a report on Tuesday. Wedbush set a $165.00 price target on shares of Oruka Therapeutics in a research report on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday, April 21st. Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th. Finally, Barclays lifted their price objective on Oruka Therapeutics from $78.00 to $160.00 and gave the company an “overweight” rating in a research note on Monday, April 27th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Oruka Therapeutics currently has an average rating of “Moderate Buy” and an average price target of $131.30.

Institutional Investors Weigh In On Oruka Therapeutics

Hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada raised its position in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares in the last quarter. Kennedy Capital Management LLC increased its stake in Oruka Therapeutics by 0.9% in the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after acquiring an additional 420 shares during the last quarter. AlphaCentric Advisors LLC raised its position in Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after purchasing an additional 626 shares in the last quarter. Russell Investments Group Ltd. raised its position in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after purchasing an additional 788 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Oruka Therapeutics by 62.4% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after purchasing an additional 904 shares during the last quarter. 56.44% of the stock is currently owned by institutional investors.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.